TITLE

Simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus

PUB. DATE
November 2005
SOURCE
ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents information on a clinical study according to which simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus. The study explored in patients with vascular disease or diabetes mellitus, what is the cost-effectiveness of simvastatin compared with placebo for reducing major vascular events (MVEs)? Fewer patients who received simvastatin had an MVE, other vascular event, or died of a vascular event than did those who received placebo. Simvastatin reduced hospitalization costs more than placebo.
ACCESSION #
18925764

 

Related Articles

  • Simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus: COMMENTARY. Bloomfield, Hanna E. // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p80 

    This article comments on a clinical study according to which simvastatin was cost-effective for reducing major vascular events in vascular disease or diabetes mellitus. Although the study by the HPS investigators is an elegant CEA based on an extremely important clinical trial, it will be of...

  • IV paricalcitol the clear winner in secondary hyperparathyroidism.  // PharmacoEconomics & Outcomes News;12/16/2006, Issue 518, p1 

    The article reports on the benefits of IV paricalcitol to patients with secondary hyperparathyroidism according to a study. Researchers modelled the costs and outcomes of using IV paricalcitol compared with oral calcitriol and oral and IV alfacalcidol for one year. IV paricalcitol was associated...

  • Gambling on Disease Management. Fetterolf, Donald // Disease Management;Oct2007, Vol. 10 Issue 5, p245 

    The author reflects on the financial impact of disease management (DM) program in the U.S. Medical management can return the overall health care costs from 2-10 percent of hospitalization. The members of the program can acquire an overall savings rate of per-member per-month basis. Activities of...

  • Cost Effectiveness of Levocetirizine in Chronic Idiopathic Urticaria: A Pooled Analysis of Two Randomised Controlled Trials. Kapp, Alexander; Demarteau, Nadia // Clinical Drug Investigation;2006, Vol. 26 Issue 1, p1 

    BACKGROUND: Chronic idiopathic urticaria is a distressing condition that severely affects patients' quality of life. The overall costs associated with this disease, both for the healthcare payer and society, are unknown. The objective of this study was to evaluate the cost effectiveness of...

  • A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Pande, Reena L.; Hiatt, William R.; Zhang, Peter; Hittel, Norbert; Creager, Mark A. // Vascular Medicine;2010, Vol. 15 Issue 3, p181 

    Pharmacologic therapy for intermittent claudication in patients with peripheral artery disease (PAD) is limited. We aimed to determine the durability of cilostazol treatment response over time, treatment effects in various subpopulations, and long-term safety. This analysis pooled original data...

  • Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial. Sepanjnia, Khatereh; Modabbernia, Amirhossein; Ashrafi, Mandana; Modabbernia, Mohammad-Jafar; Akhondzadeh, Shahin // Neuropsychopharmacology;Aug2012, Vol. 37 Issue 9, p2093 

    Thiazolidinediones have shown antidepressant effect in animal studies, as well as in some uncontrolled studies evaluating human subjects with concurrent major depressive disorder (MDD) and metabolic syndrome. Although these drugs are insulin sensitizers, they also have important...

  • Cost-Effectiveness Analysis of Schizophrenia Relapse Prevention: An Economic Evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) Study in Spain. Bernardo, Miguel; Azanza, Jose Ramón; Rubio-Terrés, Carlos; Rejas, Javier // Clinical Drug Investigation;2006, Vol. 26 Issue 8, p447 

    OBJECTIVE: The aim of this study was to estimate the cost-effectiveness of schizophrenia relapse prevention in Spain using data from the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study. METHODS: Treatment of schizophrenia was modeled over 1 year using a retrospective deterministic model...

  • Bad muti. Jones, Llewellyn // Finance Week;2/23/2004, p18 

    Comments on the rise of private hospital care costs in South Africa due to pricing regulations. Price mechanisms for medicine and health services; Compensation for lost profit by professional fee; Adjustment of ward and theater fees within the constraints of the hospital's funding arrangements.

  • New Drugs: Health and Economic Impacts. Lichtenberg, Frank R. // NBER Reporter;Winter2002/2003, p5 

    Examines the health and economic impacts of the development and use of emerging drugs. Impact of emerging drugs' approvals on the longevity of Americans; Effects of changes in both the average quantity and the average vintage of drugs consumed on work limitations; Findings on the impact of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics